Background: The etiology of delayed cerebral vasospasm (DCV) after aneurysmal subarachnoid hemorrhage (SAH) has remained elusive. Growing evidence supports a role for inflammation in the pathogenesis of DCV. We showed that CSF neutrophils predict which patients will develop DCV. Methods: We evaluated a murine model of SAH to test the hypothesis that myeloid cells are required for the cerebral damage associated with DCV. Results: SAH was associated with decreased middle cerebral artery caliber on day 1 which normalized at day 3 and recurred at day 6. In addition, behavioral testing with a Barnes maze showed executive dysfunction that progressively worsened after the seventh day post hemorrhage. To test the role of innate immune responses, we administrated a myeloid cell-depleting monoclonal antibody against Ly6G/C prior to experimental SAH. Myeloid cell depletion ameliorated angiographic vasospasm measured by MCA vessel caliber and normalized behavioral testing. Conclusion: Our findings support the role of Ly6G/C + cells in the development of DCV after SAH and suggest that immune modulation of neutrophils or other Ly6G/C + cells may be a strategy for the prevention of DCV.
Introduction
Delayed cerebral vasospasm (DCV) is a late complication of aneurysmal subarachnoid hemorrhage. Patients who experience DCV show both focal neurological signs and global acute cognitive decline during periods of DCV. The cerebral arteries in DCV patients are narrowed 4-14 days after subarachnoid hemorrhage (SAH) (Provencio and Vora, 2005 ). The precise mechanism by which bleeding from cerebral aneurysms causes this delayed reaction remains unclear but several lines of evidence implicate inflammation in the pathogenesis of the vasculopathy (Takizawa et al., 2001; Gallia and Tamargo, 2006; Manno et al., 1997; Lin et al., 2005) .
In our laboratory, we have found that neutrophils in the cerebral ventricular fluid (CSF) predict which patients with SAH will later develop DCV (Provencio et al., 2010) . A number of studies in animal models have also suggested a role for innate immune inflammation in its pathogenesis. Blockade of E-selectin, a trafficking molecule for neutrophils and other inflammatory cells across the vascular endothelium, has been shown in a murine model to ameliorate vasospasm (Lin et al., 2005) . Fasudil, a protein kinase inhibitor that is known to decrease chemotaxis of granulocytes also decreased vasospasm in a dog model (Shibuya et al., 2001 ). Administration of a humanized anti-CD11/CD18 antibody decreased vasospasm in a rabbit model (Pradilla et al., 2004) .
Direct evidence of innate inflammatory cell action is lacking in the development of DCV. Ly6G/C is a surface marker found on cells of the myeloid lineage, predominantly neutrophils and monocytes (but also reported in small quantities on activated CD8 + T cells) (Daley et al., 2008) .
Antiboidies against Ly6G/C have been exploited as markers of innate immune cells (Tazawa et al., 2003; Kurizaki et al., 2004) . Because the innate inflammatory pathway may be a reasonable target for treatment or prevention of DCV, we investigated the role of Ly6G/C + cells in DCV.
Methods
All experiments were conducted under the supervision of the Cleveland Clinic Institutional Animal Care and Use committee (IACUC). 
